| Similar Articles |
|---|
 |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.   |
The Motley Fool
December 7, 2006
Billy Fisher |
Breakout at Vanda Good news on the company's schizophrenia drug sends its shares skyrocketing. |
The Motley Fool
September 26, 2007
Billy Fisher |
More Than 40 Winks From Arena The company announced positive preliminary results from its phase 2 clinical trial for APD125, which aims to treat people suffering from chronic insomnia. Investors, take note. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
May 2, 2007
Brian Lawler |
Vanda Advancing The development-stage biotech releases first-quarter financial results. Investors, take note. |
The Motley Fool
October 27, 2006
Brian Lawler |
Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 12, 2007
Brian Lawler |
Vanda Gets Set for a Busy 2008 Although it has no marketed products, Vanda Pharmaceuticals third-quarter reports set the stage for an exciting 2008. Investors. take note. |
The Motley Fool
August 3, 2007
Brian Lawler |
Vanda Announces Some Late-Stage Maneuvers Vanda Pharmaceuticals gets ready for a busy remainder of 2007. Management awaits approval on three different compounds in the near future. Investors should be prepared for a potentially volatile road ahead. |
Chemistry World
June 14, 2012
Andrew Turley |
Good signs for Merck & Co insomnia pill In Phase III trials, insomnia drug candidate suvorexant performed well, reducing the time patients needed to fall asleep and increasing the total time sleeping, with some patients benefitting from the very first night of treatment. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note. |
The Motley Fool
December 12, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer... |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
September 27, 2007
Brian Lawler |
A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
May 18, 2009
Brian Orelli |
Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price. |
AskMen.com
Kristen Armstrong |
Insomnia Causes And Treatments Insomnia can wreak havoc on a person's life. Sufferers can try meditation, exercise or relaxation methods to alleviate symptoms and enjoy long, restful sleep on a nightly basis. |
The Motley Fool
August 1, 2007
Brian Lawler |
A Closer Look at Vanda Vanda Pharmaceuticals is a development stage drug maker worth keeping an eye on. Later this year Vanda plans to submit a New Drug Application to the FDA for its anti-psychotic medication, iloperidone. |
The Motley Fool
November 4, 2011
Brian Orelli |
You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason. |
The Motley Fool
August 13, 2004
Charly Travers |
Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition. |
Nurse Practitioner
January 2012
Hedges & Ruggiero |
Treatment Options for Insomnia Nurse practitioners must be prepared to screen patients for this common sleep disorder as well as understand the latest treatment options for optimal patient outcomes. |
Managed Care
November 2006
Martin Sipkoff |
Successful Treatment of Insomnia Starts With Formulary Design Many insurers may not consider insomnia a serious health problem, but it costs employers a bundle in lowered productivity. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
Nurse Practitioner
August 2009
Fisher & Valente |
Evaluating and managing insomnia Insomnia is the most frequent complaint in sleep disorders, and in the past, it had been viewed as a transient problem related only to other medical issues. That line of thought has changed |
The Motley Fool
July 21, 2011
Brian Orelli |
Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
American Family Physician
October 1, 2005 |
Insomnia: How to Get a Good Night's Sleep A patient guide to the condition and what to do to improve outcomes. |
